Onyx Biotec SME IPO Details, Financials, Valuation & Peers
Explore Onyx Biotec IPO details, including IPO dates, financial statements, valuation, peer comparison and more.
Overview
Founded in 2005, Onyx Biotec Limited is a prominent player in the pharmaceutical sector, specializing in the production of sterile pharmaceutical products such as Sterile Water for Injections, Dry Powder Injections, and Dry Syrup. Onyx serves major pharmaceutical companies across India and internationally. The company operates two WHO-GMP certified manufacturing facilities in Himachal Pradesh, focused on stringent quality control, sustainable practices, and modern production processes. Onyx also provides contract manufacturing services and regulatory dossier preparation, leveraging advanced equipment to meet global standards. The company is undertaking strategic upgrades, including expanding capacity for intravenous products and implementing high-speed packaging lines to enhance efficiency and product safety.
Key Points:
- Product Portfolio: Specializes in Sterile Water for Injections, Dry Powder Injections, and Dry Syrup, catering to domestic and international markets.
- Manufacturing Facilities: Operates two WHO-GMP-certified plants in Himachal Pradesh with significant production capacities and a focus on quality control and sustainable practices.
- Planned Expansion: Investing ₹607.70 lakh to expand Unit I for large-volume intravenous products and ₹124.05 lakh to set up a high-speed packaging line for cost-efficient, error-free production.
- Clientele: Trusted by leading pharmaceutical clients such as Hetero Healthcare, Sun Pharma, and Mankind Pharma, with strong client retention.
Objects of the Issue
- Upgradation of existing manufacturing Unit I to manufacture large volume parentals for intravenous use
- Setting up a high-speed cartooning packaging line at existing manufacturing Unit II for Dry Powder Injections
- Prepayment or repayment of all or a portion of certain loans availed by the Company
- General Corporate Purposes.
IPO Details
Discover essential information crucial for understanding an IPO, including the Price Band, Fresh Issue, Offer For Sale, Total IPO Size and more. Explore these key details to gain insight into the company's public offering.
| Fields | Details |
|---|---|
| IPO Dates | 13 Nov - 18 Nov 2024 |
| IPO Price Band | ₹58 - ₹61 per share |
| Fresh Issue | 48,10,000 shares |
| Offer For Sale | NIL |
| Total IPO Size | ₹29.34 crore |
| Face Value | ₹10 |
| Listing On | NSE |
IPO Timeline
Explore important dates like IPO opening, closing, listing and others, outlining the journey of the Public Offering. This will help you grasp the entire IPO journey effortlessly.
| Event | Date |
|---|---|
| IPO Opening Date | 13 Nov 2024 |
| IPO Closing Date | 18 Nov 2024 |
| Basis Of Allotment | 19 Nov 2024 |
| Refunds | 20 Nov 2024 |
| Demat Transfer | 20 Nov 2024 |
| IPO Listing Date | 21 Nov 2024 |
Financial Statements
Explore a comprehensive financial data table showcasing key metrics including revenue, expenses, net income, and others. Gain valuable insights about the company's financial performance at a glance, facilitating informed decision-making and strategic planning for subscribing to the IPO.
| Period Ended | 31st March 2022 | 31st March 2023 | 31st March 2024 | May 2024 |
|---|---|---|---|---|
| Total Income | 44.98 | 39.62 | 53.87 | 10.54 |
| Total Expenses | 41.19 | 37.07 | 49.82 | 8.79 |
| Net Profit/Loss | 3.35 | 1.84 | 3.03 | 1.31 |
| NPM (*) | 7.47 | 4.67 | 5.64 | 12.42 |
| Total Assets | 36.84 | 58.72 | 74.14 | 74.77 |
| Total Liabilities | 20.46 | 40.52 | 49.26 | 48.58 |
* NPM represents the net profit margin, calculated as a percentage. All other figures are presented in crore (₹cr)
Valuation
Uncover significant valuation metrics such as EPS (Earnings Per Share), ROE (Return on Equity), ROCE (Return on Capital Employed), D/E Ratio (Debt-to-Equity Ratio), Current Ratio, and EBITDA Margin. These key indicators offer insights into the company's financial standing and performance, aiding in informed investment decisions.
| Period Ended | 31st March 2022 | 31st March 2023 | 31st March 2024 | May 2024 |
|---|---|---|---|---|
| EPS | 2.84 | 1.56 | 2.54 | 0.98 |
| ROE (%) | 14.35 | 6.29 | 10.58 | 3.71 |
| ROCE (%) | 20.47 | 10.13 | 12.19 | 4.99 |
| D/E Ratio | 0.75 | 1.61 | 1.24 | 1.21 |
| Current Ratio | 1.44 | 0.72 | 1.31 | 1.38 |
| EBITDA MARGIN (%) | 12.57 | 11.31 | 15.41 | 26.01 |
* Compiled from DRHP/RHP for valuation purposes.
Peer Comparison
Compare key financial metrics with industry peers to gain valuable insights into the company's performance compared to its competitors.
| Name | Revenue | P/E | EPS | RoNW | NAV |
|---|---|---|---|---|---|
| Onyx Biotec Limited | 53.75 | 26.75 | 2.28 | 12.19 | 18.67 |
| Suven Pharma | 1,051.35 | 83.92 | 11.80 | 14.64 | 375.82 |
| JB Chemicals | 3,484.18 | 53.63 | 35.66 | 18.90 | 188.37 |
* Revenue in (₹cr), RoNW in (%), EPS, NAV in (₹). P/E ratio is based on the highest price from the IPO price band.
IPO Reservation
| Investor Type | Shares Offered |
|---|---|
| Qualified Institutional Buyer (QIB) | Not more than 49.89% |
| Non-Institutional Investor (NII/HNI) | Not less than 15.07% |
| Retail Individual Investor (RII) | Not less than 35.04% |
Subscription Data from NSE and BSE
| Investor Type | Subscribed |
|---|---|
| Qualified Institutional Buyer (QIB) | 32.49 |
| Non-Institutional Investor (NII/HNI) | 602.86 |
| Retail Individual Investor (RII) | 118.26 |
| Total | 198 |
* All figures represent multiples of the subscription. Check subscriptions for other ongoing issues here.
IPO Registrar
MAS Services Limited
Phone: +91 112 638 7281/83, 114 132 0335
Email: ipo@masserv.com
Website: www.masserv.com
Company Promoters
- SANJAY JAIN
- NARESH KUMAR
- FATEH PAL SINGH
- HARSH MAHAJAN
- LAKSHYA JAIN
- PARMJEET KAUR
Lead Managers
- Horizon Management Private Limited
Company Address
Onyx Biotec Limited
Bir Plassi Near Sainimajraropar, Nalagarh Road, District Solan – 174 101, Himachal Pradesh, India.
Phone: +91 172 265 6384
Email: generalinfo@onyxbiotec.com
Website: www.onyxbiotec.com
FAQs
- What is the issue size of the Onyx Biotec SME IPO?The Onyx Biotec SME IPO has an issue size of ₹29.34 crore. This includes a fresh issue of 48,10,000 shares and an offer for sale (OFS) of NIL.
- What is the price band of the Onyx Biotec IPO?The price band for the Onyx Biotec IPO is ₹58 - ₹61 per share.
- What are the bidding dates for the Onyx Biotec IPO?The Onyx Biotec IPO will open for bidding on 13 Nov 2024 and close on 18 Nov 2024.
- What is the allotment date for the Onyx Biotec IPO?The allotment date for the Onyx Biotec IPO is 19 Nov 2024.
- What is the minimum lot size and investment required for the Onyx Biotec IPO?The minimum lot size for the Onyx Biotec IPO is 2000 shares and the minimum investment required is ₹1,22,000.
- What is the listing date for the Onyx Biotec IPO?The listing date for the Onyx Biotec IPO is 21 Nov 2024.
- What is the Onyx Biotec IPO grey market premium?The grey market premium (GMP) for the Onyx Biotec IPO is currently at ₹5, with an expected listing gain of approximately 8.2%. Remember, the grey market premium is not an official indicator, but it reflects market perception and demand for the IPO shares.